Quick Answer
HeartSciences Inc. reported Cash and Equivalents of $1.10 million for fiscal year 2025.
HeartSciences Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.10M | -81.1% |
| 2024 | $5.81M | +249.8% |
| 2023 | $1.66M | +80.8% |
| 2022 | $918.3K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $3.40M | +30.8% | +74.1% |
| October 31, 2025 | $1.95M | -51.8% | -30.1% |
| July 31, 2025 | $2.79M | -35.7% | +154.3% |
| April 30, 2025 | $1.10M | -81.1% | -57.7% |
| January 31, 2025 | $2.60M | -63.3% | -35.9% |
| October 31, 2024 | $4.05M | +3946.3% | -6.6% |
| July 31, 2024 | $4.34M | +653.9% | -25.3% |
| April 30, 2024 | $5.81M | +249.8% | -17.9% |
- HeartSciences Inc. showed a decrease of -81.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, HeartSciences Inc.’s cash and equivalents has grown by 19.6% (from $918.3 thousand to $1.10 million).
- The most recent figure is from HeartSciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: